NextLevel Pharma

Knowledge Solutions for Life Sciences: Follow our new @nextlevel_LS account for the latest updates!

[pharmaphorum @pharmaphorum]

Sitting in on the @NextLevelPharma #PharmAccess conference today ahead of moderating a panel later. Here Jim Thomson from @GSK talks about early access

[Evidence Life Science @Evidence_LS]

Robert Ström from National Swedish Pharmaceutical Insurance, speaking on #PatientSafety in therapy and in #clinical trials @ our #NORDICMA Forum in Stockholm! https://t.co/qzuSoJ8LyP

[Evidence Life Science @Evidence_LS]

Priit Tohver from Ministry of Social Affairs on Estonian approach to #digital innovation in health & care @ #NORDICMA Forum 2018! https://t.co/qzuSoJ8LyP

[Evidence Life Science @Evidence_LS]

Elina Asola from Ministry of Social Affairs and Health discussing the Finnish #reimbursement & #pricing system @ our #NORDICMA Forum in Stockholm! https://t.co/qzuSoJ8LyP

[Evidence Life Science @Evidence_LS]

Thank you to our event partner @SyneosHealth! #PharmAccess Leaders Forum, London 2018

[Evidence Life Science @Evidence_LS]

Panel discussion: The role of #MarketAccess teams in generating #evidence @ our #PharmAccess Forum in London! https://t.co/mz5iDyk2g9

[Evidence Life Science @Evidence_LS]

Friedhelm Leverkus from @pfizer discussing the use of outcome research in the AMNOG process @ #PharmAccess Forum in London! https://t.co/mz5iDyk2g9

[Evidence Life Science @Evidence_LS]

Noolie Gregory @SyneosHealth, on changing trends in #RealWorldEvidence @ our #PharmAccess Forum in London! https://t.co/mz5iDyk2g9

[Evidence Life Science @Evidence_LS]

Amazing #networking atmosphere at our #NORDICMA Forum in Stockholm! #MarketAccess #NextLevelLS https://t.co/qzuSoJqmqn

[Evidence Life Science @Evidence_LS]

Steen Werner Hansen from Herlev and Gentofte Hospital, on assessing #value of targeted therapies @ #NORDICMA Forum in Stockholm! https://t.co/qzuSoJqmqn

[Evidence Life Science @Evidence_LS]

Kieron Lewis from @Clinigen on Early Access Programs as a valuable component of #MarketAccess & launch strategy @ #PharmAccess Forum 2018 in London! https://t.co/mz5iDy2qRz

[Evidence Life Science @Evidence_LS]

Jim Thomson from @GSK, on #MarketAccess models for rare diseases treatments at #PharmAccess Forum, London 2018 https://t.co/mz5iDyk2g9

[Evidence Life Science @Evidence_LS]

Brian Godman, @karolinskainst, on managed entry agreements and their impact on payers and pharma companies @ our #PharmAccess Forum in London! https://t.co/mz5iDyk2g9

[Evidence Life Science @Evidence_LS]

Ahmed Abdulla, @DigipharmTeam on #blockchain technology & its applications in #healthcare @ #PharmAccess Forum 2018! https://t.co/mz5iDyk2g9

[Evidence Life Science @Evidence_LS]

Jolanda Koenders from @Novartis speaking about innovative #pricing model in the Netherlands @ our #PharmAccess Forum in London! https://t.co/mz5iDyk2g9

[Evidence Life Science @Evidence_LS]

Jan Liliemark, @SBU_se , on how ethical considerations affect the #value of drugs @ our #NORDICMA Forum in Stockholm! https://t.co/qzuSoJ8LyP

[Evidence Life Science @Evidence_LS]

Chris Bidad, @pfizer , speaking about Innovative #Pricing & #Reimbursement Agreements @ our #PharmAccess Forum in London 2018! https://t.co/mz5iDy2qRz

[Evidence Life Science @Evidence_LS]

Marc Van de Casteele, @RIZIV_INAMI , on Harmonising #HEOR requirements for regional #HTA collaboration @ our #PharmAccess Forum in London 2018! https://t.co/mz5iDyk2g9

[Evidence Life Science @Evidence_LS]

Make sure you meet the @DigipharmTeam team at our #PharmAccess Leaders Forum in London! #MarketAccess

[Evidence Life Science @Evidence_LS]

Panel discussion: Multi-stakeholder views on improving the effectiveness of #HEOR studies & models @ our #PharmAccess Forum in London 2018!